BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Takaya H, Kawaratani H, Tsuji Y, Nakanishi K, Saikawa S, Sato S, Sawada Y, Kaji K, Okura Y, Shimozato N, Kitade M, Akahane T, Moriya K, Namisaki T, Mitoro A, Matsumoto M, Fukui H, Yoshiji H. von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C. United European Gastroenterol J. 2018;6:1401-1409. [PMID: 30386613 DOI: 10.1177/2050640618779660] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Takaya H, Namisaki T, Moriya K, Shimozato N, Kaji K, Ogawa H, Ishida K, Tsuji Y, Kaya D, Takagi H, Fujinaga Y, Nishimura N, Sawada Y, Kawaratani H, Akahane T, Matsumoto M, Yoshiji H. Association between ADAMTS13 activity–VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinoma. World J Gastroenterol 2020; 26(45): 7232-7241 [PMID: 33362379 DOI: 10.3748/wjg.v26.i45.7232] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Lelas A, Greinix HT, Wolff D, Eissner G, Pavletic SZ, Pulanic D. Von Willebrand Factor, Factor VIII, and Other Acute Phase Reactants as Biomarkers of Inflammation and Endothelial Dysfunction in Chronic Graft-Versus-Host Disease. Front Immunol 2021;12:676756. [PMID: 33995421 DOI: 10.3389/fimmu.2021.676756] [Reference Citation Analysis]
3 Czajka P, Przybyłkowski A, Nowak A, Postula M, Wolska M, Mirowska-Guzel D, Czlonkowska A, Eyileten C. Antiplatelet drugs and liver fibrosis. Platelets 2021;:1-10. [PMID: 33577391 DOI: 10.1080/09537104.2021.1883574] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Ohuchi H, Hayama Y, Miike H, Suzuki D, Nakajima K, Iwasa T, Konagai N, Sakaguchi H, Miyazaki A, Shiraishi I, Kurosaki KI, Nakai M. Prognostic value of von Willebrand factor in adult patients with congenital heart disease. Heart 2020;106:910-5. [PMID: 32188625 DOI: 10.1136/heartjnl-2019-316007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Takaya H, Namisaki T, Kitade M, Shimozato N, Kaji K, Tsuji Y, Nakanishi K, Noguchi R, Fujinaga Y, Sawada Y, Saikawa S, Sato S, Kawaratani H, Moriya K, Akahane T, Yoshiji H. Acylcarnitine: Useful biomarker for early diagnosis of hepatocellular carcinoma in non-steatohepatitis patients. World J Gastrointest Oncol 2019; 11(10): 887-897 [PMID: 31662827 DOI: 10.4251/wjgo.v11.i10.887] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Edvardsen MS, Hindberg K, Hansen ES, Morelli VM, Ueland T, Aukrust P, Brækkan SK, Evensen LH, Hansen JB. Plasma levels of von Willebrand factor and future risk of incident venous thromboembolism. Blood Adv 2021;5:224-32. [PMID: 33570640 DOI: 10.1182/bloodadvances.2020003135] [Reference Citation Analysis]
7 Balaceanu LA. Biomarkers vs imaging in the early detection of hepatocellular carcinoma and prognosis. World J Clin Cases 2019; 7(12): 1367-1382 [PMID: 31363465 DOI: 10.12998/wjcc.v7.i12.1367] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
8 Takaya H, Namisaki T, Kitade M, Kaji K, Nakanishi K, Tsuji Y, Shimozato N, Moriya K, Seki K, Sawada Y, Saikawa S, Sato S, Kawaratani H, Akahane T, Noguchi R, Matsumoto M, Yoshiji H. VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma. BMC Gastroenterol. 2019;19:167. [PMID: 31638892 DOI: 10.1186/s12876-019-1082-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
9 Ye J, Wu S, Pan S, Huang J, Ge L. Risk scoring based on expression of long non‑coding RNAs can effectively predict survival in hepatocellular carcinoma patients with or without fibrosis. Oncol Rep 2020;43:1451-66. [PMID: 32323856 DOI: 10.3892/or.2020.7528] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
10 Semmler G, Binter T, Kozbial K, Schwabl P, Hametner-Schreil S, Zanetto A, Gavasso S, Chromy D, Bauer DJM, Simbrunner B, Scheiner B, Bucsics T, Stättermayer AF, Pinter M, Steindl-Munda P, Schöfl R, Russo FP, Simioni P, Trauner M, Ferenci P, Reiberger T, Mandorfer M. Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. Hepatology 2021;73:1275-89. [PMID: 32659847 DOI: 10.1002/hep.31462] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
11 Takaya H, Namisaki T, Takeda S, Kaji K, Ogawa H, Ishida K, Tsuji Y, Takagi H, Ozutsumi T, Fujinaga Y, Furukawa M, Kitagawa K, Nishimura N, Sawada Y, Shimozato N, Kawaratani H, Moriya K, Akahane T, Mitoro A, Yoshiji H. The Combination of Albumin-Bilirubin Score and Prothrombin Time Is a Useful Tool for Predicting Liver Dysfunction after Transcatheter Arterial Chemoembolization in Child-Pugh Class A Patients with Hepatocellular Carcinoma within Up-to-Seven Criteria. J Clin Med 2021;10:4838. [PMID: 34768358 DOI: 10.3390/jcm10214838] [Reference Citation Analysis]
12 Cheng Y, Liu N, Yang C, Jiang J, Zhao J, Zhao G, Chen F, Zhao H, Li Y. MicroRNA-383 inhibits proliferation, migration, and invasion in hepatocellular carcinoma cells by targeting PHF8. Mol Genet Genomic Med 2020;8:e1272. [PMID: 32441881 DOI: 10.1002/mgg3.1272] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Chen Y, Wei D, Deng M. Comparative Analysis of Serum Proteins Between Hepatitis B Virus Genotypes B and C Infection by DIA-Based Quantitative Proteomics. Infect Drug Resist 2021;14:4701-15. [PMID: 34795487 DOI: 10.2147/IDR.S335666] [Reference Citation Analysis]
14 Mussbacher M, Brunnthaler L, Panhuber A, Starlinger P, Assinger A. Till Death Do Us Part-The Multifaceted Role of Platelets in Liver Diseases. Int J Mol Sci 2021;22:3113. [PMID: 33803718 DOI: 10.3390/ijms22063113] [Reference Citation Analysis]
15 Zhao L, Shi J, Chang L, Wang Y, Liu S, Li Y, Zhang T, Zuo T, Fu B, Wang G, Ruan Y, Zhang Y, Xu P. Serum-Derived Exosomal Proteins as Potential Candidate Biomarkers for Hepatocellular Carcinoma. ACS Omega 2021;6:827-35. [PMID: 33458533 DOI: 10.1021/acsomega.0c05408] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
16 Takaya H, Namisaki T, Shimozato N, Kaji K, Kitade M, Moriya K, Sato S, Kawaratani H, Akahane T, Matsumoto M, Yoshiji H. ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma. World J Gastrointest Oncol 2019; 11(5): 424-435 [PMID: 31139312 DOI: 10.4251/wjgo.v11.i5.424] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]